Amicus Therapeutics

FOLDNASDAQAcquired

Rare disease biologics and small-molecule chaperone platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Pipeline at the time of the last update

DrugIndicationPhaseExpected data
GalafoldFabry diseaseApprovedNot disclosed▼
Pombiliti + Opfoldalate-onset Pompe diseaseApprovedNot disclosed▼


Comparable companies

Ultragenyx PharmaceuticalBioMarin PharmaceuticalProtalix BioTherapeutics
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Amicus Therapeutics has 24 Phase 2 or 3 studies on ClinicalTrials.gov: 17 completed, 3 stopped early, 4 ongoing.

17

Completed

3

Stopped early

4

Ongoing

Stopped early

  • AT1001-041Phase 3 · started 2011 · terminated

    migalastat hydrochloride in fabry disease · n=85

    Reason given: Amicus Therapeutics discontinued Study AT1001-041 for logistical reasons.

  • NCT00688597Phase 2 · started 2008 · terminated

    Duvoglustat in pompe disease · n=3

    Reason given: Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.

  • NCT00526071Phase 2 · started 2007 · terminated

    migalastat HCl in fabry disease · n=23

    Reason given: The Sponsor (Amicus Therapeutics) terminated this study for logistical reasons.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.